Rectal cancer T4b incomplete response exenteration

2021 ◽  
Author(s):  
Vikas Shah
Keyword(s):  
Rectal Cancer ◽  
Incomplete Response

Transanal Local Excision for Distal Rectal Cancer and Incomplete Response to Neoadjuvant Chemoradiation – Does Baseline Staging Matter?

2014 ◽  
Vol 57 (11) ◽  
pp. 1253-1259 ◽  
Author(s):  
Rodrigo O. Perez ◽  
Angelita Habr-Gama ◽  
Guilherme P. São Julião ◽  
Igor Proscurshim ◽  
Augusto Q. Coelho ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Local Excision ◽  
Neoadjuvant Chemoradiation ◽  
Transanal Local Excision ◽  
Incomplete Response ◽  
Distal Rectal Cancer ◽  
Baseline Staging

Elevated CEA Levels and Low Distance of the Tumor from the Anal Verge are Predictors of Incomplete Response to Chemoradiation in Patients with Rectal Cancer

2012 ◽  
Vol 20 (3) ◽  
pp. 864-871 ◽  
Author(s):  
Angelo Restivo ◽  
Luigi Zorcolo ◽  
Ivana Maria Francesca Cocco ◽  
Romina Manunza ◽  
Carla Margiani ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Anal Verge ◽  
Incomplete Response

scholarly journals Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Ihsane El Otmani ◽  
Fatima El Agy ◽  
Sanae El Baradai ◽  
Laila Bouguenouch ◽  
Nada Lahmidani ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Surgical Resection ◽  
Distant Metastasis ◽  
Therapeutic Response ◽  
High Expression ◽  
Prognostic Impact ◽  
P53 Expression ◽  
Incomplete Response ◽  
Pathologic Features ◽  
Her 2

Pathologic features depending on tumor response to preoperative chemoradiotherapy are important to determine the outcomes in patients with rectal cancer. Evaluating the potential predictive roles of biomarker expression and their prognostic impact is a promising challenge. We reported here the immunohistochemical staining of a panel marker of mismatch repair protein (MMR), Ki67, HER-2, and p53. Additionally, identification of somatic mutations of KRAS, NRAS, and BRAF genes were performed by direct sequencing and pyrosequencing in pretreated biopsy tissues from 57 patients diagnosed for rectal cancer. Clinical features and pathological criteria for postneoadjuvant treatment surgical resection specimen’s data were collected. Immunohistochemical expression and mutational status were correlated with therapeutic response, overall survival, and disease progression. The mean age of patients was 56 years. Seven (12.3%) out of 57 patients had a complete therapeutic response. Our analysis showed that when using complete therapeutic response (Dworak 4) and incomplete therapeutic response (Dworak 3, 2, and 1) as grouping factor, high p53 expression at the pretreatment biopsy was significantly associated to an incomplete response (p=0.002). For 20 and 2 out of 57, KRAS and NRAS mutations were detected, respectively. The majority of these mutations affected codon 12. KRAS mutations detected at codon 146 (A146T, A146V) was associated with the appearance of recurrence and distant metastasis (p=0.019). A high expression of HER-2 corresponding to score 3+ was observed in 3 pretreatment biopsy specimens. This class was significantly associated with a short relapse-free survival (p=0.002). Furthermore, the high expression of Ki67 was moderately correlated with an older age (p=0.016, r=0.319). In addition, this shows that high p53 expression in the pretreatment biopsy was associated with an incomplete response in surgical resection specimens after neoadjuvant treatment, and a HER-2 score 3+ can be a predictive factor of distant metastasis and local recurrence. Larger, prospective, and more studies are needed.

Sign in / Sign up

Export Citation Format

Share Document